Antibiotic Development: FDA Says New Guidances Will Help, But Industry Questions Statistical Focus
Executive Summary
Industry is questioning the fundamental statistical underpinnings of FDA's approval pathways for antibiotics even as the agency prepares to roll out several guidances to help clarify them
You may also be interested in...
FDA Raises Breakpoints In Final Labeling For Forest's Ceftaroline
FDA demonstrated a willingness to be flexible about antibiotic breakpoints in its Oct. 29 approval of Forest Laboratories' ceftaroline fosamil.
FDA Raises Breakpoints In Final Labeling For Forest's Ceftaroline
FDA demonstrated a willingness to be flexible about antibiotic breakpoints in its Oct. 29 approval of Forest Laboratories' ceftaroline fosamil.
User Fee Discussions Include Funding Parts Of FDA Regulatory Science Plan
Commissioner Margaret Hamburg’s plans to improve regulatory science at FDA could benefit from application user fees, based on PDUFA negotiations.